Bio-Techne Corporation TECH
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +23.55%
- 1 year
- +19.19%
- Open
- 72.72
- Prev close
- 72.71
- Mkt cap
- 11.41B
- Vol
- 2.57M
- Avg vol
- 2.84M
- EPS
- 1.16
- P/E
- 62.64
- Div yield
- 0.44%
More statistics
- Low
- 72.66
- High
- 72.73
- Forward P/E
- 31.44
- Beta
- 1.29
- Short ratio
- 2.42
- Inst. own
- 112.55%
- Dividend
- 0.32
- Ex-div date
- Aug 23, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 72.44
- 200-d avg
- 63.13
- 1y target
- 70.50
2Y chart
Events in this range
- Nov 8, 2024Dividend: 0.08
- Feb 14, 2025Dividend: 0.08
- May 19, 2025Dividend: 0.08
- Aug 6, 2025Earnings: 0.53; estimate 0.5; surprise 6%
- Aug 18, 2025Dividend: 0.08
- Nov 5, 2025Earnings: 0.42; estimate 0.4214; surprise -0.33%
- Nov 17, 2025Dividend: 0.08
- Feb 4, 2026Earnings: 0.46; estimate 0.43; surprise 6.98%
- Feb 13, 2026Dividend: 0.08
- May 6, 2026Earnings: 0.53; estimate 0.55; surprise -3.64%
- May 18, 2026Dividend: 0.08
- Jun 26, 2026Downgrade: Stephens & Co. · Overweight → Equal-Weight
- Jun 29, 2026Downgrade: Citigroup · Buy → Neutral
- Jun 30, 2026Downgrade: Benchmark · Buy → Hold
- Jun 30, 2026Downgrade: TD Cowen · Buy → Hold
- Jul 9, 2026Downgrade: RBC Capital · Outperform → Sector Perform
- Aug 12, 2026Earnings: 0.52; estimate 0.519; surprise 0.19%
- Aug 13, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Aug 17, 2026Dividend: 0.08
- Aug 24, 2026Dividend: 0.08
Signals (82)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| MACD: Buy Signal | May 22, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 5 months ago |
| SMA: Bullish | Apr 30, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 23, 2026 | 7 months ago |
| RSI: Oversold | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Mar 5, 2026 | 8 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| RSI: Oversold | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 28, 2026 | 9 months ago |
| RSI: Overbought | Jan 14, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 30, 2025 | 10 months ago |
| SMA: Bearish | Dec 8, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 8, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 7, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 29, 2025 | 1 year ago |
| RSI: Overbought | Oct 23, 2025 | 1 year ago |
| RSI: Overbought | Oct 2, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 30, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 30, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 20, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 6, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 10, 2025 | 1 year ago |
| MACD: Buy Signal | May 27, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 23, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 2, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 12, 2025 | 1 year ago |
| RSI: Oversold | Mar 11, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 7, 2025 | 1 year ago |
| RSI: Oversold | Feb 26, 2025 | 1 year ago |
| RSI: Oversold | Feb 21, 2025 | 1 year ago |
| RSI: Oversold | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Feb 7, 2025 | 1 year ago |
| SMA: Bullish | Feb 5, 2025 | 1 year ago |
| SMA: Bearish | Jan 29, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 7, 2025 | 1 year ago |
Key statistics
- Market cap
- 11.41B
- Enterprise value
- 11.43B
- Trailing P/E
- 62.64
- Forward P/E
- 31.44
- PEG ratio
- 2.17
- Price / sales
- 9.39
- Price / book
- 5.38
- EPS (TTM)
- 1.16
- Beta
- 1.29
- Dividend yield
- 0.44%
- Payout ratio
- 27.59%
- Profit margin
- 14.97%
- Revenue (TTM)
- 1.22B
- Revenue growth
- 1.30%
- Free cash flow
- 229.65M
- Total cash
- 265.48M
- Total debt
- 289.09M
- Return on equity
- 9.03%
- Shares outstanding
- 157.06M
- Short % of float
- 4.82%
- 50-day average
- 72.44
- 200-day average
- 63.13
Analyst view
Consensus: hold
- Target (low)
- 50.00
- Target (mean)
- 70.50
- Target (high)
- 73.00
- Strong buy0
- Buy0
- Hold12
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.44764.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.44 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | 0.519 | 0.52 | 0.00 | +0.19% |
| May 6, 2026 | Mar 31, 2026 | 0.55 | 0.53 | -0.02 | -3.64% |
| Feb 4, 2026 | Dec 31, 2025 | 0.43 | 0.46 | +0.03 | +6.98% |
| Nov 5, 2025 | Sep 30, 2025 | 0.4214 | 0.42 | 0.00 | -0.33% |
| Aug 6, 2025 | Jun 30, 2025 | 0.50 | 0.53 | +0.03 | +6.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Jul 9, 2026 | RBC Capital | down | Outperform | Sector Perform |
| Jun 30, 2026 | TD Cowen | down | Buy | Hold |
| Jun 30, 2026 | Benchmark | down | Buy | Hold |
| Jun 29, 2026 | Citigroup | down | Buy | Neutral |
| Jun 26, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bio-techne.com
News
- Conestoga SMid Cap Composite Q3 2026 Portfolio Activity
- Press release: CMB.TECH fleet update
- CMB.TECH SPECIAL GENERAL MEETING RESULTS
- Bio-Techne Opens New Bristol Facility
- Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development
- INCY or TECH: Which Is the Better Value Stock Right Now?
- INTURAI PROVIDES DEFENCE TECH COMPETITION RESULTS AND COMPANY UPDATE
- Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?
- Zhibao Technology Signs Definitive Agreement to Acquire NEXSYS TECH for Planned AI Computing Infrastructure Business
- Bio-Techne Receives Shareholders' Approval For Proposed Acquisition By Merck KGaA
Your note
Sign in to keep a note on TECH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director | Stock Award(Grant) | Oct 29, 2025 | 46,503 |
| BOHNEN SHANE | General Counsel | Conversion of Exercise of derivative security | Aug 13, 2026 | 10,360 |
| GEIST WILLIAM | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 24,943 |
| HIGGINS JOHN L | Director | Conversion of Exercise of derivative security | Sep 27, 2026 | 77,254 |
| HIPPEL JAMES | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 170,183 |
| KEEGAN JOSEPH D | Director | Stock Award(Grant) | Oct 29, 2025 | 15,411 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.93% | 14,025,816 | 1.02B | Jun 29, 2026 |
| FMR, LLC | 8.15% | 12,794,784 | 929.73M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.51% | 10,218,558 | 742.53M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.68% | 7,343,324 | 533.60M | Jun 29, 2026 |
| HBK Investments L P | 4.35% | 6,825,000 | 495.94M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.14% | 6,506,360 | 472.78M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 4,968,867 | 361.06M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.58% | 4,056,808 | 294.79M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.28% | 3,586,562 | 260.62M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 1.72% | 2,707,457 | 196.74M | Sep 29, 2026 |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 1.66% | 2,604,519 | 189.26M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 2,089,474 | 151.83M | Sep 29, 2026 |